Reversibility of lower reproductive tract abnormalities in women with Schistosoma haematobium infection after treatment with praziquantel--an interim report.
Little is known whether and to what extent antiparasitic treatment cures female genital schistosomiasis (FGS). Using a standard protocol, of twenty-one women with FGS nine were re-examined at two to nine weeks after they had been treated with praziquantel at a single dose of 40 mg/kg. Symptoms related to pathology of the urinary tract and to a lesser extent of genital pathology subsided in most patients. Schistosoma haematobium ova were no longer detectable in urine of any of the patients post-treatment. Efficiency of chemotherapy against adult worms was confirmed by the disappearance of circulating anodic antigen (CAA) in serum. Sandy patches showed resolution in two of four cases after chemotherapy. Papillomata due to schistosomiasis alone improved, but persisted in mixed infection with human papilloma virus (HPV) or when HPV was the only underlying cause. In one patient ulcera could not be related with certainty to schistosomiasis at admission, but resolved after treatment with parziquantel. Leukoplakia (two cases) was not influenced by chemotherapy, or even increased during follow-up, regardless of whether ova had been detected or not. Although the follow-up period was rather short, time intervals were not standardized, and a relatively small number of patients was investigated, it could be shown that genital pathology due to sequestered S. haematobium ova is, at least partially, reversible already two to nine weeks after killing the adult worms by praziquantel. This is paralleled by a normalization of inflammatory immune responses detectable in histological sections and vaginal lavage.
Richter
J
J
Institute of Tropical Medicine, Berlin, Germany.
Poggensee
G
G
Kjetland
E F
EF
Helling-Giese
G
G
Chitsulo
L
L
Kumwenda
N
N
Gundersen
S G
SG
Deelder
A M
AM
Reimert
C M
CM
Haas
H
H
Krantz
I
I
Feldmeier
H
H
D000293:Adolescent; D000328:Adult; D000818:Animals; D000909:Antibodies, Helminth / Q000032:analysis; D000947:Antigens, Helminth / Q000032:analysis; D000980:Antiplatyhelmintic Agents / Q000627:therapeutic use*; D001708:Biopterins / Q000031:analogs & derivatives / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D047091:Eosinophil Granule Proteins; D005260:Female; D005500:Follow-Up Studies; D005831:Genital Diseases, Female / Q000175:diagnosis* / Q000473:pathology / Q000652:urine; D005836:Genitalia, Female / Q000473:pathology; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007073:Immunoglobulin E / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007971:Leukoplakia / Q000188:drug therapy; D008875:Middle Aged; D019798:Neopterin; D010063:Ovum / Q000469:parasitology; D010212:Papilloma / Q000473:pathology; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications; D011223:Praziquantel / Q000627:therapeutic use*; D012260:Ribonucleases; D012548:Schistosoma haematobium / Q000254:growth & development / Q000302:isolation & purification; D012552:Schistosomiasis / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D012553:Schistosomiasis haematobia / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D014412:Tumor Virus Infections / Q000150:complications; D014551:Urinary Tract / Q000473:pathology
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D000980:Antiplatyhelmintic Agents; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D001708:Biopterins; D007073:Immunoglobulin E; D011223:Praziquantel; D019798:Neopterin; D012260:Ribonucleases